Contrarius Investment Management’s Intellia Therapeutics NTLA Stock Holding History

Contrarius Investment Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$42.1M	Buy	2,047,218 +131,808	+7%	+$3.04M	2.39%	15
2024 Q2	$42.9M	Buy	1,915,410 +564,879	+42%	+$13.4M	2.68%	16
2024 Q1	$37.2M	Buy	1,350,531 +1,136,130	+530%	+$31.6M	2.15%	17
2023 Q4	$6.54M	Sell	214,401 -17,461	-8%	-$502K	0.35%	37
2023 Q3	$7.33M	Sell	231,862 -62,177	-21%	-$2.41M	0.41%	37
2023 Q2	$12M	Buy	+294,039	New	+$11.9M	0.65%	33

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Contrarius Investment Management's NTLA Position: Q3 2024 in Review

Contrarius Investment Management increased its Intellia Therapeutics (NTLA) stake by 6.9% in Q3 2024, buying an estimated $3.04M and bringing the position to 2,047,218 shares worth $42.1M. The position accounts for 2.39% of the portfolio, ranked #15.

Contrarius Investment Management first reported a position in NTLA in Q2 2023 and has held it in 6 quarters since. The position peaked at $42.9M in Q2 2024. 283 funds tracked by Wall St. Rank hold NTLA as of Q3 2024.

Contrarius Investment Management held 2,047,218 shares of Intellia Therapeutics worth $42.1M as of Q3 2024.
Contrarius Investment Management bought 131,808 Intellia Therapeutics shares in Q3 2024, an estimated $3.04M.
Intellia Therapeutics made up 2.39% of Contrarius Investment Management's portfolio in Q3 2024, its #15 holding.
Contrarius Investment Management first reported a position in Intellia Therapeutics in Q2 2023 and has held it in 6 quarters since.
Contrarius Investment Management's Intellia Therapeutics position peaked at $42.9M in Q2 2024.
283 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2024.

Based on Contrarius Investment Management's 13F filing for Q3 2024, filed 8 Nov 2024.